-
1.发明授权Nucleic acids encoding factor X analogues having a modified protease cleavage site 有权编码具有修饰的蛋白酶切割位点的因子X类似物的核酸公开(公告)号：US07220569B2
公开(公告)日：2007-05-22
申请号：US10407123
申请日：2003-04-04
CPC分类号： C12N9/6432 , A61K38/00 , C12Y304/21006
摘要： Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.
摘要翻译： 提供编码因子X类似物的核酸，其在天然因子Xa激活切割位点的区域具有修饰。 该修饰导致在因子X序列的该区域中不自然切割的蛋白酶的加工位点。
-
公开(公告)号：US06573071B1
公开(公告)日：2003-06-03
申请号：US09367791
申请日：1999-11-12
IPC分类号： C12P2100
CPC分类号： C12N9/6432 , A61K38/00 , C12Y304/21006
摘要： Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.
摘要翻译： 因子X类似物在天然因子Xa活化切割位点的区域具有修饰，所述修饰代表在因子X序列的该区域中不自然切割的蛋白酶的加工位点，所述制剂含有本发明的因子X类似物， 并描述其制备方法。
-
3.发明授权公开(公告)号：US06905846B2
公开(公告)日：2005-06-14
申请号：US10348504
申请日：2003-01-21
申请人： Michele Himmelspach , Michael Pfleiderer , Falko-Guenter Falkner , Johann Eibl , Friedrich Dorner , Uwe Schlokat
发明人： Michele Himmelspach , Michael Pfleiderer , Falko-Guenter Falkner , Johann Eibl , Friedrich Dorner , Uwe Schlokat
IPC分类号： C12N15/09 , A61K38/00 , A61K38/36 , A61K38/46 , A61K38/48 , A61P7/00 , A61P7/04 , C07K14/475 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/64 , C12N15/57 , C12P21/02 , C12P21/06
CPC分类号： C12N9/6432 , A61K38/00 , C12Y304/21006
摘要： Nucleic acids encoding factor XΔ analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided.
摘要翻译： 提供编码具有氨基酸Arg180至Arg234缺失的因子XDelta类似物的核酸，以及Gly173和Arg179之间的氨基酸序列区域的修饰。
-
公开(公告)号：US06562598B1
公开(公告)日：2003-05-13
申请号：US09367777
申请日：1999-11-18
申请人： Michele Himmelspach , Michael Pfleiderer , Falko-Guenter Falkner , Johann Eibl , Friedrich Dorner , Uwe Schlokat
发明人： Michele Himmelspach , Michael Pfleiderer , Falko-Guenter Falkner , Johann Eibl , Friedrich Dorner , Uwe Schlokat
IPC分类号： C12P2106
CPC分类号： C12N9/6432 , A61K38/00 , C12Y304/21006
摘要： Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.
摘要翻译： 提供因子XDELTA类似物，以及含有此类类似物的药物制剂和制备此类类似物的方法。 因子XDELTA类似物具有氨基酸Arg180至Arg234的缺失和在因子X氨基酸序列的Gly173和Arg179之间的氨基酸序列区域的修饰。 这样的类似物可以包括通常不存在于因子X中的处理位点，从而允许将类似物选择性转化为活性形式。 类似物和制剂可用于治疗许多凝血障碍。
-
公开(公告)号：US5854403A
公开(公告)日：1998-12-29
申请号：US653298
申请日：1996-05-24
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00 , C07K1/14
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt. The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant rvWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active. Further, the invention relates to a pharmaceutical preparation that contains rvWF, which comprises mulitimers with a high structural integrity.
摘要翻译： 本发明涉及一种用于分离高纯度血管性血友病因子的方法，其中重组血管性血友病因子（rvWF）通过阴离子交换色谱在季氨基型阴离子交换剂上在包含缓冲物质和任选盐的缓冲溶液中进行色谱纯化。 缓冲溶液优选不含稳定剂，氨基酸和其它添加剂。 根据该方法，可以获得高纯度的重组rvWF，其不含血浆蛋白质，特别是不含因子VIII，且具有生理活性。 此外，本发明涉及含有rvWF的药物制剂，其包含具有高结构完整性的多组分。
-
公开(公告)号：US5880265A
公开(公告)日：1999-03-09
申请号：US898129
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
-
公开(公告)号：US6103693A
公开(公告)日：2000-08-15
申请号：US898130
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00 , A61K38/17 , C07K14/745
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
摘要翻译： 本发明涉及一种用于分离高纯度血管性血友病因子的方法，其中重组血管性血友病因子（rvWF）通过阴离子交换色谱在季氨基型阴离子交换剂上在包含缓冲物质和任选盐的缓冲溶液中进行色谱纯化。 缓冲溶液优选不含稳定剂，氨基酸和其它添加剂。 根据该方法，可以获得高纯度的重组vWF，其不含血浆蛋白质，特别是不含因子VIII，且具有生理活性。 此外，本发明涉及含有rvWF的药物制剂，其由具有高结构完整性的多聚体组成。
-
8.发明授权Fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterologous sequence 失效包含弗林蛋白酶衍生物或弗林素类似物衍生物和异源序列的融合蛋白公开(公告)号：US06210929B1
公开(公告)日：2001-04-03
申请号：US08753247
申请日：1996-11-22
IPC分类号： C12N1562
CPC分类号： C07K14/755 , A61K38/00 , C07K2319/00 , C12N9/6454
摘要： Fusion proteins of an optionally C-terminally deleted furin derivative, or of a derivative of a furin analogue, and a heterologous sequence, methods of preparing the same and methods of recovering proproteins from proteins by using the proproteins according to the invention are described.
摘要翻译： 描述了任选C末端缺失的弗林蛋白酶衍生物，弗林蛋白酶类似物衍生物和异源序列的融合蛋白，其制备方法以及通过使用本发明的蛋白从蛋白质中回收蛋白质的方法。
-
公开(公告)号：US5877152A
公开(公告)日：1999-03-02
申请号：US898131
申请日：1997-07-22
申请人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
发明人： Bernhard Fischer , Artur Mitterer , Friedrich Dorner , Hans-Peter Schwarz , Peter Turecek , Johann Eibl , Falko-Guenter Falkner , Uwe Schlokat , Wolfgang Mundt , Manfred Reiter , Renate Den-Bouwmeester
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K38/43 , A61P7/04 , C07K1/18 , C07K1/22 , C07K14/47 , C07K14/755 , C12P21/00 , A61K38/17
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity
摘要翻译： 本发明涉及一种用于分离高纯度血管性血友病因子的方法，其中重组血管性血友病因子（rvWF）通过阴离子交换色谱在季氨基型阴离子交换剂上在包含缓冲物质和任选盐的缓冲溶液中进行色谱纯化。 缓冲溶液优选不含稳定剂，氨基酸和其它添加剂。 根据该方法，可以获得高纯度的重组vWF，其不含血浆蛋白质，特别是不含因子VIII，且具有生理活性。 此外，本发明涉及含有rvWF的药物制剂，其由具有高结构完整性的多聚体组成
-
公开(公告)号：US06958322B1
公开(公告)日：2005-10-25
申请号：US09632722
申请日：2000-08-04
申请人： Michele Himmelspach , Uwe Schlokat
发明人： Michele Himmelspach , Uwe Schlokat
CPC分类号： C12N9/6432 , C12Y304/21006
摘要： This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.
摘要翻译： 本发明描述了相对于根据图1的氨基酸编号，具有至少一个氨基酸在Glu226和Arg234之间以及可能的Ile235的取代的因子Xa类似物。 1，含有因子X类似物的活化形式的制剂，以及这些分子的制备方法。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.028 秒)
